Life Science

The M & A frenzy in Life Sciences

During the last years we have witnessed a strong increase in mergers and acquisitions within the Life Sciences industry, especially in pharma and biotech. According to a Thomson One and KPMG analysis, the total deal value of the M&A dealings of the first half of 2015 was $ 221 bn.
The biggest M&A issues recently have been Shire´s $ 32 bn merger with Baxalta, which created the global market leader in rare diseases and other specialised disorders, generic maker Teva´s purchase of the generics division of Allergan for $ 40.5 bn and Bayer´s takeover bid of $ 66 bn for U.S. seeds company Monsanto.

Continue reading


From the preclinical stage to Phase I – Thoughts on more security, in addition to the planned EU standard

TeGenero and now also Biotrial in Rennes (Phase I study for a product of BIAL, Portugal) are two examples of severe incidents in early clinical testing.

While in the case of TeGenero in France where, to give a simplified description, a Zytokin storm has brought everything to a close, a study design was used, which is incomprehensible to an observing expert. Products that are “designed” primarily on a computer are no less risky. A continuous risk assessment is important in all development stages.

Continue reading

scroll top